Hospital Corp

What Hospital Corp does

Hospital Corp (弘和仁爱医疗集团, stock code 3869.HK) is a Hong Kong-listed, Beijing-headquartered hospital investment and operations platform founded in 2014. It acquires controlling stakes in secondary and tertiary hospitals in economically developed regions of eastern China — primarily the Yangtze River Delta, Pearl River Delta, and Bohai Rim — and operates them under standardized management. The platform runs a network of six hospitals with over 3,000 beds, anchored by Shanghai Yangsi Hospital (a 900-bed non-profit general hospital generating 538 million RMB annual revenue and 1.88 million outpatient visits) and including specialty assets such as Zhejiang Jinhua Guangfu Tumor Hospital (350 beds, respiratory medicine) and Jiande Traditional Chinese Medicine Hospital (Tier-2 Grade A, fully acquired February 2022). Strategic direction emphasizes a 'dual-wheel' model of acquisition plus management enhancement, with the 2020 leadership transition formalizing an 'acquire, manage well, scale up' roadmap.

The company's revenue mechanics combine direct healthcare services revenue (outpatient, inpatient, specialty care), hospital management/consulting fees (2017 segment revenue of 149 million RMB, up 14% YoY), and centralized supply chain services via its Honghe Pharmaceutical (弘和医药) subsidiary, which secured pharmaceutical and Class III medical device distribution licenses in June 2021 and holds strategic supplier partnerships with Mindray and GE Healthcare. Hospital services are priced under China's regulated public healthcare framework; pricing is not publicly disclosed. The group is backed by Hony Investments (弘毅投资, a Lenovo Holdings affiliate), which raised up to HK$500M via the 2017 IPO and arranged a HK$800M convertible bond subscription by Lenovo Holdings in December 2018 — both vehicles underwriting further M&A.

The platform's technology positioning centers on a Hospital Operations Management Platform supporting hospital investment and management integration, with no disclosed proprietary AI/ML capabilities. Distribution is direct-to-patient via the affiliated hospital network; go-to-market leans on brand operations seminars, community outreach, and referral relationships with tier-1 academic hospitals including Renji and Zhongshan (Shanghai Jiao Tong/Fudan systems). The customer base is end-patients seeking general, chronic, and specialist care in urban eastern China, with B2B touchpoints limited to referral and procurement relationships.

Name

Hospital Corp

Legal name

Hospital Corporation of Orissa Inc.

Website

https://hcclhealthcare.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Hospital Corp (弘和仁爱医疗集团, 3869.HK) is a Hong Kong-listed hospital investment and operations platform that acquires and manages secondary and tertiary hospitals across eastern China, operating six facilities with 3,000+ beds and serving general, chronic, and specialty patient populations under China-regulated pricing.

Ownership category

akta.pro rank

Product category

Hospital Operations and Healthcare Services

NAICS

General Medical and Surgical Hospitals (6221), General Medical and Surgical Hospitals (622110), Hospitals (622), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Health Services (8000)

akta.pro industry

PRIMARYHLAFAAAB

Community & Regional General Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Acute Care Hospitals & Health Systems

SECONDARYHLAFAAAL

Hospital-Owned Physician Networks & Medical Groups

Healthcare & Life Sciences/Healthcare Providers & Systems/Acute Care Hospitals & Health Systems

SECONDARYHLAFAHAI

Inpatient Infectious Disease & Isolation Specialty Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

Keywords

• Hospital management services
• Healthcare operations platform
• Integrated care delivery
• Medical investment services
• Pharmaceutical supply chain

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D

Revenue model

1. Hospital Management Services: The group provides management and consulting services to hospitals, generating revenue through management fees and service charges. 2017 management services revenue was 149 million RMB with 14% year-over-year growth.
2. Healthcare Services Revenue: Direct revenue from hospital operations including outpatient services, inpatient care, and specialized medical services. Yangsi Hospital alone generates 538 million RMB annually with 1.88 million outpatient visits.
3. Supply Chain Services (弘和医药): Pharmaceutical and medical device supply chain services including centralized procurement, distribution, and supply to affiliated hospitals. Revenue generated from price differentials and service fees.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Hospital Corp is a hospital investment, acquisition, and integrated operations platform that owns and manages a multi-specialty hospital network in China. Its core activity is acquiring hospitals and applying standardized operating, clinical, and supply-chain systems to deliver inpatient and outpatient care. Through its Honghe Pharmaceutical subsidiary, it also operates a pharmaceutical supply chain serving the hospital network.

Product overview

弘和仁爱医疗集团 (Hospital Corp) is a medical services investment and operations integration platform, listed on the Hong Kong Stock Exchange (stock code 3869.HK) in 2017. The company operates a network of five hospitals — Shanghai Yangsi Hospital, Zhejiang Jinhua Guangfu Hospital, Yongkang Hospital, Jiande Traditional Chinese Medicine Hospital, and Cixi Honghe Hospital — delivering general and specialized medical services. The group's strategy combines 'investment and acquisition' with 'management improvement' (双轮驱动), acquiring hospitals that meet its standards, applying healthcare-industry-specific operational controls, and building regional medical service centers. A subsidiary, 弘和医药 (Honghe Pharmaceutical), provides centralized supply chain services including medical equipment, pharmaceuticals, and medical devices to the hospital network. The group is evolving from a traditional multi-hospital chain toward a technology-driven large-scale medical services group, with focus on common diseases, chronic disease management, and integrated care models.

Differentiator

Problem solved

Functional benefit

Products and services

• Shanghai Yangsi Hospital Operations

Quantifiable outcome

• Patient satisfaction increased 13% after management improvements at Yangsi Hospital
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered minor.

• Mindray (迈瑞集团)minorStrategic or Co-development Partner · 1 June 2021弘和医药 established strategic partnership with Mindray for equipment procurement, gaining price advantages through centralized purchasing while ensuring product quality and after-sales service.
• Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital (上海交通大学医学院附属仁济医院)minorStrategic or Co-development PartnerYangsi Hospital established collaborative relationships with top-tier tertiary hospitals including Renji Hospital, Zhongshan Hospital, and Ruijin Hospital for technical cooperation and referral services.
• Fudan University Affiliated Zhongshan Hospital (复旦大学附属中山医院)minorStrategic or Co-development PartnerCollaborative relationship for technical cooperation and medical referrals, bringing quality medical resources to the local community.
• GE HealthcareminorStrategic or Co-development Partner弘和医药 established strategic partnership with GE Healthcare for medical equipment procurement, leveraging collective purchasing power for cost efficiency.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hospital-corporation-of-china-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hospital Corp